| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $100.3M | +53.9% |
| Cost of Revenue | $44.7M | +52.9% |
| Gross Profit | $55.5M | +54.8% |
| R&D Expense | $34.8M | +32.9% |
| SG&A Expense | $31.0M | +73.6% |
| Operating Income | -$71.7M | -58.4% |
| Income Tax | $0 | — |
| Net Income | -$73.2M | -33.7% |
| EPS (Basic) | -$1.81 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $31.6M | +3.8% |
| Short-term Investments | $187.5M | +156.4% |
| Accounts Receivable | $17.1M | +42.7% |
| Inventory | $21.7M | +63.1% |
| Current Assets | $267.9M | +101.5% |
| Total Assets | $328.7M | +119.7% |
| Current Liabilities | $30.9M | +46.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$50.9M | -5.5% |
| Capital Expenditures | $5.3M | +56.0% |
| Investing Cash Flow | -$162.8M | -4583.7% |
| Financing Cash Flow | $214.9M | +286.4% |
| Free Cash Flow | -$56.2M | -8.8% |
| +79.0% |
| EPS (Diluted) | -$1.81 | +79.0% |
| Total Liabilities |
| $41.1M |
| -44.1% |
| Stockholders' Equity | $287.6M | +217.2% |